Full-Time
Sales Representative
Joint Replacement
Updated on 9/3/2026
Stryker
10,001+ employees
Manufactures orthopedic and surgical medical devices
No salary listed
Company Historically Provides H1B Sponsorship
Philadelphia, PA, USA
In Person
Field-based role with approximately 10% travel and on-call evenings, weekends, and holidays as needed.
Bachelor's
 Sales & Account Management (1) |
|---|
Get referred to Stryker
See people who can refer or advise you
- A bachelor's degree or a minimum of four years of experience in a clinical healthcare or sales role, or a combination of education and experience.
- A proven track record of achieving sales goals.
- Knowledge of and experience with sales techniques, marketing strategies, product demonstrations, and sales control systems.
- The ability to lift and transport up to 50 pounds occasionally and up to 20 pounds frequently.
- A valid driver's license.
- Fluency in written and spoken English.
- Manage and grow existing customer accounts by delivering excellent service and building trusted partnerships.
- Achieve and exceed sales targets by identifying, qualifying, and closing new business opportunities.
- Communicate with stakeholders and customers, respond to customer inquiries, and resolve challenges.
- Conduct product evaluations in operating room and office settings, demonstrating the value of the products.
- Provide product knowledge and training to surgeons, nurses, and operating room staff.
- Manage and maintain product sample inventory and adhere to compliance requirements and AdvaMed principles of responsibility.
- Participate in and represent Stryker at industry events and conferences as required.
- Perform on-call duties, including evenings, weekends, and holidays as determined by territory needs, to address urgent technical needs and ensure continuous customer support.
- Medical device sales experience.
- Experience in a clinical work environment.
- Expertise with orthopedic joint replacement products.
- A minimum of three years of business-to-business sales experience.
Stryker designs, manufactures, and sells medical devices across multiple areas, including surgical equipment, neurotechnology, and orthopedic implants, to hospitals and clinics worldwide. Its products are developed through engineering and clinical input, then manufactured and distributed to healthcare providers who use them during procedures to improve patient care and surgical efficiency. Stryker differentiates itself from competitors with a broad, integrated portfolio, a global sales and service network, and a strong emphasis on quality and ongoing product development to support safer, more efficient procedures. The company’s goal is to advance patient outcomes by delivering reliable, effective medical devices that expand access to care globally.
Company Size
10,001+
Company Stage
IPO
Headquarters
Kalamazoo, Michigan
Founded
1941
Get referred to Stryker
See people who can refer or advise you
Simplify's Take
What believers are saying
- Second-quarter 2026 sales reached $6.59 billion, with 9.0% organic growth and expanding margins.
- Duke Health completed the first SportSuite Vision surgery on September 1, 2026, validating adoption.
- Stryker won a $100 million Defense Logistics Agency contract modification in August 2026.
What critics are saying
- March 11, 2026 cyberattack disrupted Microsoft systems, manufacturing, and distribution, exposing operational fragility.
- Stryker still carries cyberattack litigation risk after March 2026 employee claims and possible regulator follow-on actions.
- Peripheral vascular backlogs and production recovery threaten Q3 2026 delivery, margins, and customer trust.
What makes Stryker unique
- Mako robotics crossed 2.5 million procedures worldwide across 47 countries by July 2026.
- SportSuite Vision became FDA De Novo authorized on July 17, 2026, for Apple Vision Pro.
- Stryker signed ZuriMED on August 31, 2026, deepening shoulder and rotator cuff specialization.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Medical & prescription plans
Supplemental health benefits
Flexible Spending accounts
Employee Assistance Program
Short-term & long-term disability
Tuition reimbursement
401(k) plan
Employee Stock Purchase Plan
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Stryker has completed the first surgical procedure using its FDA-authorized SportSuite Vision application on Apple Vision Pro at Duke Health. The hip arthroscopy was performed by orthopaedic surgeon Dr Chad Mather III at the academic medical centre. SportSuite Vision received FDA De Novo authorization on 17 July, making it the first application approved for intraoperative use with Apple Vision Pro. The technology allows surgeons to view arthroscopic video, HipCheck, HipMap and CT imaging within their field of vision during procedures. The spatial computing application aims to reduce reliance on traditional monitors positioned throughout operating rooms. By bringing multiple data sources into the surgeon's field of view, it supports a more streamlined and ergonomic surgical workflow during complex arthroscopic procedures.
Stryker has signed a definitive agreement to acquire ZuriMED, a privately held developer of the FiberLocker System for rotator cuff repair. The commercialised soft tissue augmentation technology is designed to provide increased biomechanical strength and reduce clinical failure in rotator cuff procedures. According to Stryker, the acquisition will strengthen its shoulder portfolio and expand support for shoulder specialists across sports medicine and arthroplasty. Rotator cuff augmentation is described as one of the fastest-growing areas in sports medicine and a significant opportunity in shoulder care. The transaction is subject to customary closing conditions. Stryker and ZuriMED will operate as separate entities until closing is complete.
Stryker started 2026 with strong underlying demand despite a cyber disruption. The medical technology company reported 9% organic sales growth in the second quarter, with MedSurg & Neurotechnology rising 9.2% and Orthopaedics up 8.6%. International sales grew 8.9%, supported by markets including Australia, Germany, Canada, India and Brazil. Mako Robotics continues to drive growth, with more than 2.5 million procedures performed globally and systems installed across 47 countries. US knee sales increased 6.2% on continued Mako adoption. The company has a market capitalisation of $125.7 billion. Its bottom line is expected to improve 10.4% over the next five years. However, shares have fallen 6.7% this year, whilst the industry declined 15.2%.
Stryker's Michigan sales unit secured a $100 million contract modification from the US Defense Logistics Agency, reinforcing its position as a key government healthcare supplier. The award complements Stryker's hospital and surgical product revenue, adding government-backed visibility. The company maintains its steady dividend track record, with a quarterly $0.88 per-share payout affirmed in August 2026. However, investors face ongoing concerns including regulatory friction, supply chain pressure, and pricing strain from government payers. Stryker's narrative projects $32.6 billion revenue and $6.5 billion earnings by 2029, requiring 8.9% yearly revenue growth. Fair value estimates from the Simply Wall St Community range from $331 to $426 per share. The contract highlights stable government contracting but does not fundamentally alter Stryker's near-term catalysts or main investment risks.
Stryker shares fell 6.42% following its second-quarter 2026 earnings release, which showed sales of $6.59 billion and net income of $1.28 billion. The medical technology company is now trading approximately 23% below one valuation estimate and 18% beneath the average analyst target. Analysts currently place Stryker's fair value at $386.80, compared to its recent closing price of $325.70. Price targets vary significantly amongst analysts, ranging from $315 to $465. The year-to-date share price return has fallen 6.46%, though the company maintains a five-year total shareholder return of 30.66%. Potential risks to the company's outlook include prolonged EU regulatory delays and sustained supply chain disruptions that could affect product launches and margins.